ASP8273 tolerability and antitumor activity in tyrosine kinase inhibitor‐naïve Japanese patients with EGFR mutation‐positive non‐small‐cell lung cancer

Epidermal growth factor receptor (EGFR) activating mutations occur in approximately 50% of East Asian patients with non‐small‐cell lung cancer (NSCLC) and confer sensitivity to tyrosine kinase inhibitors (TKIs). ASP8273 is an irreversible EGFR‐TKI, given orally, that inhibits EGFR activating mutatio...

Descripción completa

Detalles Bibliográficos
Autores principales: Azuma, Koichi, Nishio, Makoto, Hayashi, Hidetoshi, Kiura, Katsuyuki, Satouchi, Miyako, Sugawara, Shunichi, Hida, Toyoaki, Iwamoto, Yasuo, Inoue, Akira, Takeda, Koji, Ikeda, Satoshi, Nakagawa, Tomoki, Takeda, Kentaro, Asahina, Seitaro, Komatsu, Kanji, Morita, Satoshi, Fukuoka, Masahiro, Nakagawa, Kazuhiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6113441/
https://www.ncbi.nlm.nih.gov/pubmed/29807396
http://dx.doi.org/10.1111/cas.13651

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6113441/
https://www.ncbi.nlm.nih.gov/pubmed/29807396
http://dx.doi.org/10.1111/cas.13651

Ejemplares similares